| Co-Investigator(Kenkyū-buntansha) |
下瀬川 恵久 大阪大学, 医学(系)研究科(研究院), 寄附講座教授 (30370258)
加藤 弘樹 大阪大学, 医学(系)研究科(研究院), 講師 (20448054)
渡部 直史 大阪大学, 医学(系)研究科(研究院), 助教 (90648932)
金井 泰和 大阪大学, 医学(系)研究科(研究院), 寄附講座助教 (60397643)
渡部 浩司 東北大学, 学内共同利用施設等, 准教授 (40280820)
|
|---|
| Budget Amount *help |
¥157,560,000 (Direct Cost: ¥121,200,000、Indirect Cost: ¥36,360,000)
Fiscal Year 2016: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2015: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
Fiscal Year 2014: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
Fiscal Year 2013: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
Fiscal Year 2012: ¥115,700,000 (Direct Cost: ¥89,000,000、Indirect Cost: ¥26,700,000)
|
|---|
| Outline of Final Research Achievements |
In the process of new drug development, species difference in pharmacokinetics induced a failure of clinical trial due to lack of expected treatment effect and/or unexpected adverse effect. The aim of the present study was to establish a method to elucidate species difference in whole-body distribution of new drug candidate compounds by means of animal and human PET studies.
We tested two drugs, Donepezil hydrochloride for Alzheimer's disease and borono-phenylalanine for boron neutron capture therapy of intractable cancers. Both compounds showed pharmacokinetic species difference in the PET studies. The present study contributes to rapid and efficient drug development, and to provide safe medicines by reducing unexpected adverse effects not predicted by animal studies.
|
